INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)

Trial Profile

INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
  • Indications Cardiovascular disorders
  • Focus Therapeutic Use
  • Acronyms INTENSITY-HIGH
  • Most Recent Events

    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 30 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top